治療薬の世界市場分析:製品別(消耗品、機器、データ管理サービス)、技術別(イムノアッセイ、プロテオーム技術)、薬品別(抗てんかん剤、抗生物質、免疫抑制剤、抗不整脈剤)、エンドユーザー別(病院研究室、私設研究室)、セグメント予測

Grand View Researchが発行した調査報告書(GVIEW707842)
◆英語タイトル:Therapeutic Drug Monitoring Market Analysis By Product (Consumables, Equipment, Data Management Services), By Technology (Immunoassays, Proteomic Technologies) By Drug Class (Anti-epileptic s, Antibiotics, Immunosuppressants, Anti-arrhythmics) By End-use (Hospital Labs, Private Labs), and Segment Forecasts To 2024
◆商品コード:GVIEW707842
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2016年8月18日
◆ページ数:80
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:Biotechnology
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥559,350見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥898,350見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,124,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、治療薬の世界市場について調査・分析し、治療薬の世界市場動向、治療薬の世界市場規模、市場予測、セグメント別治療薬市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.
The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.

Further key findings from the study suggest:

The consumables segment covered over 65% of the market share in 2015 as a consequence of the extensive requirement of the consumables in the research laboratories and due to the repeat purchase of the kits and reagents.

The immunoassay segment held the largest market share in 2015. The presence of several commercially available immunoassays combined with their associated benefits including the cost effectiveness and easy-to-handle nature of the products are the key drivers for the growth of this segment.

The proteomics category is expected to be the fastest growing technology segment due to the advent of various proteomic technologies, such as isotope-coded affinity tags, next generation sequencing, and protein microarray platforms that enable rapid mining of the proteome.

The hospital is the largest end-use segment with a share of over 60% in 2015. In larger hospitals, various underlying technologies are employed to perform immunoassays; these comprise chemiluminescence, nephelometry, colorimetry, and fluorescence, which are available for the testing of a wide ranging drug panel.

The drug monitoring for the immunosuppressants is one of the fastest growing application segments owing to the introduction of novel TDM point-of-care testing devices for the evaluation of the concentration of administered immunosuppressants and the complementary metabolites, in order to achieve a prominent therapeutic effect while preventing drug toxicity events in patients that have undergone transplantations.

In 2015, North America was the highest revenue generating region with revenue generated over USD 900 million. The rising number of R&D activities coupled with the high awareness about personalized therapy is the major determining factor for the large share captured by the North America region.

Few of the leading market players are Roche Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMérieux, Inc., and Alere, Inc. The persistent R&D efforts are being undertaken along with numerous other strategic endeavors being adopted by the market players with the objective of enhancing the present drug monitoring practices and to develop novel technologies.

【レポートの目次】

Table of Content

Chapter 1.Methodology And Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Therapeutic drug monitoring market – Industry Snapshot and Key Buying Criteria, 2013 – 2024
Chapter 3. Therapeutic Drug Monitoring Market, Industry Outlook
3.1. Market segmentation
3.2. Market size and growth prospects
3.3. Therapeutic drug monitoring market: Market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis – Porter’s
3.6. Therapeutic drug monitoring market PESTEL analysis, 2015
Chapter 4. Therapeutic Drug Monitoring Market, Product Outlook
4.1. Therapeutic drug monitoring market share by product, 2015 & 2024
4.2. Consumables
4.2.1. Consumables market estimates and forecasts, 2013 – 2024 (USD Million)
4.3. Equipment
4.3.1. Equipment market estimates and forecasts, 2013 – 2024 (USD Million)
4.4. Others
4.4.1. Others market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 5. Therapeutic Drug Monitoring Market, Technology Outlook
5.1. Therapeutic drug monitoring market share by technology, 2015 & 2024
5.2. Immunoassays
5.2.1. Immunoassays market estimates and forecasts, 2013 – 2024 (USD Million)
5.3. Proteomic technologies
5.3.1. Proteomic technologies market estimates and forecasts, 2013 – 2024 (USD Million)
5.4. Others
5.4.1. Others market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 6. Therapeutic Drug Monitoring Market, Drug Class Outlook
6.1. Therapeutic drug monitoring market share by drug class, 2015 & 2024
6.2. Anti – epileptics
6.2.1. Anti – epileptic market estimates and forecasts, 2013 – 2024 (USD Million)
6.3. Antibiotics
6.3.1. Antibiotics market estimates and forecasts, 2013 – 2024 (USD Million)
6.4. Immunosuppressants
6.4.1. Immunosuppressants market estimates and forecasts, 2013 – 2024 (USD Million)
6.5. Psychoactive drugs
6.5.1. Psychoactive drugs market estimates and forecasts, 2013 – 2024 (USD Million)
6.6. Anti-arrhythmic drugs
6.6.1. Anti-arrhythmic drugs market estimates and forecasts, 2013 – 2024 (USD Million)
6.7. Others
6.7.1. Others drug market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 7. Therapeutic Drug Monitoring Market, End – use Outlook
7.1. Therapeutic drug monitoring market share by end – use, 2015 & 2024
7.2. Hospital labs
7.2.1. Hospital labs market estimates and forecasts, 2013 – 2024 (USD Million)
7.3. Private labs
7.3.1. Private labs market estimates and forecasts, 2013 – 2024 (USD Million)
7.4. Others
7.4.1. Others market estimates and forecasts, 2013 – 2024 (USD Million)
Chapter 8. Drug Monitoring Market Regional Outlook
8.1. Therapeutic drug monitoring market share by region, 2015 & 2024
8.2. North America
8.2.1. North America market estimates and forecasts, by product, 2013 – 2024 (USD Million)
8.2.1.1. U.S. market estimates and forecasts
8.2.1.2. Canada market estimates and forecasts
8.2.2. North America market estimates and forecasts, by technology type, 2013 – 2024 (USD Million)
8.2.2.1. U.S. market estimates and forecasts
8.2.2.2. Canada market estimates and forecasts
8.2.3. North America market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.2.3.1. U.S. market estimates and forecasts
8.2.3.2. Canada market estimates and forecasts
8.2.4. North America market estimates and forecasts, by end – use type, 2013 – 2024 (USD Million)
8.2.4.1. U.S. market estimates and forecasts
8.2.4.2. Canada market estimates and forecasts
8.3. Europe
8.3.1. Europe market estimates and forecasts, by product , 2013 – 2024 (USD Million)
8.3.1.1. UK market estimates and forecasts
8.3.1.2. Germany market estimates and forecasts
8.3.2. Europe market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.3.2.1. UK market estimates and forecasts
8.3.2.2. Germany market estimates and forecasts
8.3.3. Europe market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.3.3.1. UK market estimates and forecasts
8.3.3.2. Germany market estimates and forecasts
8.3.4. Europe market estimates and forecasts, by end – use, 2013 – 2024 (USD Million)
8.3.4.1. UK market estimates and forecasts
8.3.4.2. Germany market estimates and forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific market estimates and forecasts, by product, 2013 – 2024 (USD Million)
8.4.1.1. Japan market estimates and forecasts
8.4.1.2. China market estimates and forecasts
8.4.2. Asia Pacific market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.4.2.1. Japan market estimates and forecasts
8.4.2.2. China market estimates and forecasts
8.4.3. Asia Pacific market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.4.3.1. Japan market estimates and forecasts
8.4.3.2. China market estimates and forecasts
8.4.4. Asia Pacific market estimates and forecasts, by end – use , 2013 – 2024 (USD Million)
8.4.4.1. Japan market estimates and forecasts
8.4.4.2. China market estimates and forecasts
8.5. Latin America
8.5.1. Latin America market estimates and forecasts, by product, 2013 – 2024 (USD Million)
8.5.1.1. Brazil market estimates and forecasts
8.5.2. Latin America market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.5.2.1. Brazil market estimates and forecasts
8.5.3. Latin America market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.5.3.1. Brazil market estimates and forecasts
8.5.4. Latin America market estimates and forecasts, by end – use, 2013 – 2024 (USD Million)
8.5.4.1. Brazil market estimates and forecasts
8.6. MEA
8.6.1. MEA market estimates and forecasts, by product , 2013 – 2024 (USD Million)
8.6.1.1. South Africa market estimates and forecast
8.6.2. MEA market estimates and forecasts, by technology, 2013 – 2024 (USD Million)
8.6.2.1. South Africa market estimates and forecast
8.6.3. MEA market estimates and forecasts, by drug class, 2013 – 2024 (USD Million)
8.6.3.1. South Africa market estimates and forecast
8.6.4. MEA market estimates and forecasts, by end – use, 2013 – 2024 (USD Million)
8.6.4.1. South Africa market estimates and forecast
Chapter 9. Competitive Landscape
9.1. Roche Diagnostics
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. biomérieux, Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Abbott Laboratories, Inc.
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Danaher Corporation
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Alere, Inc.
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Agilent Technologies, Inc.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Thermo Fisher Scientific, Inc.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Siemens Healthcare GmbH
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Bio-Rad Laboratories, Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives

List of Figures

FIG. 1 Therapeutic drug monitoring: Market segmentation
FIG. 2 Therapeutic drug monitoring market revenue, 2013 - 2024 (USD million)
FIG. 3 Therapeutic drug monitoring : Market dynamics
FIG. 4 Key Opportunities Prioritized
FIG. 5 Therapeutic drug monitoring market - Porter’s Analysis
FIG. 6 Therapeutic drug monitoring market - PESTEL Analysis
FIG. 7 Therapeutic drug monitoring market share, by product, 2015 & 2024
FIG. 8 Therapeutic drug monitoring consumables market, 2013 - 2024 (USD million)
FIG. 9 Therapeutic drug monitoring equipment market, 2013 - 2024 (USD million)
FIG. 10 Therapeutic drug monitoring others market, 2013 - 2024 (USD million)
FIG. 11 Therapeutic drug monitoring market share, by technology, 2015 & 2024
FIG. 12 Therapeutic drug monitoring immunoassays market, 2013 - 2024 (USD million)
FIG. 13 Therapeutic drug monitoring proteomic technologies market, 2013 - 2024 (USD million)
FIG. 14 Therapeutic drug monitoring others market, 2013 - 2024 (USD million)
FIG. 15 Therapeutic drug monitoring market share, by drug class, 2015 & 2024
FIG. 16 Therapeutic drug monitoring Anti-epileptic s market, 2013 - 2024 (USD million)
FIG. 17 Therapeutic drug monitoring antibiotics market, 2013 - 2024 (USD million)
FIG. 18 Therapeutic drug monitoring immunosuppressants market, 2013 - 2024 (USD million)
FIG. 19 Therapeutic drug monitoring psychoactive drugs market, 2013 - 2024 (USD million)
FIG. 20 Therapeutic drug monitoring Anti-arrhythmic drugs market, 2013 - 2024 (USD million)
FIG. 21 Therapeutic drug monitoring others drug market, 2013 - 2024 (USD million)
FIG. 22 Therapeutic drug monitoring revenue share, byend-use, 2015 & 2024
FIG. 23 Therapeutic drug monitoring hospital labs market, 2013 - 2024 (USD million)
FIG. 24 Therapeutic drug monitoring private labs market, 2013 - 2024 (USD million)
FIG. 25 Therapeutic drug monitoring others market, 2013 - 2024 (USD million)
FIG. 26 Therapeutic drug monitoring revenue share, by region, 2015 & 2024
FIG. 27 North America therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 28 U.S. therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 29 Canada therapeutic drug monitoring market 2013 - 2024 (USD million)
FIG. 30 Europe therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 31 UK therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 32 Germany therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 33 Asia Pacific therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 34 Japan therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 35 China therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 36 Latin America therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 37 Brazil therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 38 MEA therapeutic drug monitoring market, 2013 - 2024 (USD million)
FIG. 39 South Africa therapeutic drug monitoring market, 2013 - 2024 (USD million)

List of Tables

TABLE 1 Therapeutic drug monitoring market - Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 3 Therapeutic drug monitoring market,by technology, 2013 - 2024 (USD million)
TABLE 4 Therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 5 Therapeutic drug monitoring, by end - use, 2013 - 2024 (USD million)
TABLE 6 Therapeutic drug monitoring, by region, 2013 - 2024 (USD million)
TABLE 7 Therapeutic drug monitoring market - Key market driver analysis
TABLE 8 Therapeutic drug monitoring market - Key market restraint analysis
TABLE 9 North America therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 10 North America therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 11 North America therapeutic drug monitoring, by drug class, 2013 - 2024 (USD million)
TABLE 12 North America therapeutic drug monitoring, by end - use, 2013 - 2024 (USD million)
TABLE 13 U.S. therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 14 U.S. therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 15 U.S. therapeutic drug monitoring, by drug class, 2013 - 2024 (USD million)
TABLE 16 U.S. therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 17 Canada therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 18 Canada therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 19 Canada therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 20 Canada therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 21 Europe therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 22 Europe therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 23 Europe therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 24 Europe therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 25 UK therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 26 UK therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 27 UK therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 28 UK therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 29 Germany therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 30 Germany therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 31 Germany therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 32 Germany therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 33 Aisa Pacific therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 34 Aisa Pacific therapeutic drug monitoring market market, by technology, 2013 - 2024 (USD million)
TABLE 35 Aisa Pacific therapeutic drug monitoring market market, by drug class, 2013 - 2024 (USD million)
TABLE 36 Aisa Pacific therapeutic drug monitoring market market, by end - use, 2013 - 2024 (USD million)
TABLE 37 Japan therapeutic drug monitoring market market, by product, 2013 - 2024 (USD million)
TABLE 38 Japan therapeutic drug monitoring market market, by technology, 2013 - 2024 (USD million)
TABLE 39 Japan therapeutic drug monitoring market market, by drug class, 2013 - 2024 (USD million)
TABLE 40 Japan therapeutic drug monitoring market market, by end - use, 2013 - 2024 (USD million)
TABLE 41 China therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 42 China therapeutic drug monitoring market market, by technology, 2013 - 2024 (USD million)
TABLE 43 China therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 44 China therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 45 Latin America therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 46 Latin America therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 47 Latin America therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 48 Latin America therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 49 Brazil therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 50 Brazil therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 51 Brazil therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 52 Brazil therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million
TABLE 53 MEA therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 54 MEA therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 55 MEA therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 56 MEA therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 57 South Africa therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 58 South Africa therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 59 South Africa therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 60 South Africa therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 治療薬の世界市場分析:製品別(消耗品、機器、データ管理サービス)、技術別(イムノアッセイ、プロテオーム技術)、薬品別(抗てんかん剤、抗生物質、免疫抑制剤、抗不整脈剤)、エンドユーザー別(病院研究室、私設研究室)、セグメント予測(Therapeutic Drug Monitoring Market Analysis By Product (Consumables, Equipment, Data Management Services), By Technology (Immunoassays, Proteomic Technologies) By Drug Class (Anti-epileptic s, Antibiotics, Immunosuppressants, Anti-arrhythmics) By End-use (Hospital Labs, Private Labs), and Segment Forecasts To 2024)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆